Enclomiphene
Enclomiphene citrate
Enclomiphene (Enclomiphene citrate) is a hormonal & sexual research compound. Estrogen-receptor antagonist at the hypothalamus — removes estrogen's brake so LH/FSH rise and testicular testosterone increases.
Enclomiphene quick facts
| Reported research dose | 12.5mg-25mg |
| Route | Oral |
| Frequency | 1x Daily |
| Half-life | ~10 hrs |
| Forms | Oral |
| Evidence level | Human trials |
Raise your own testosterone while keeping fertility — the isomer that does the job without clomid's baggage.
How Enclomiphene works
Estrogen-receptor antagonist at the hypothalamus — removes estrogen's brake so LH/FSH rise and testicular testosterone increases.
Proposed benefits
Natural testosterone support by raising LH/FSH without crashing estrogen.
✅ Clinically validated
- Phase 3 trials were completed by Repros Therapeutics in men with secondary hypogonadism, showing raised total testosterone while preserving sperm concentration — which testosterone replacement does not.
- The FDA declined approval, on trial-design and endpoint grounds rather than a safety finding. That distinction is routinely lost: this is a compound with positive phase 3 data that did not clear a regulatory bar, not one that failed to work.
📊 Correlative data
- Heavy real-world use through telehealth as a testosterone-sparing alternative to TRT. The consistent clinical report matches the trials — testosterone rises, fertility is maintained, and a minority get mood or visual side effects.
🧪 Theoretical / extrapolated
- The trans-isomer of clomiphene, isolated. Clomiphene is a mixture of enclomiphene (an oestrogen receptor antagonist at the pituitary, which raises LH) and zuclomiphene (a long-lived partial agonist with a half-life of weeks).
- Separating them is the entire point: zuclomiphene accumulates and is blamed for the mood and visual effects of clomiphene, so the isolated isomer is predicted to deliver the LH rise with less of the baggage.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Enclomiphene — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- Two different mechanisms with one shared consequence: less estrogen signalling. Aromatase inhibitors (anastrozole, exemestane) stop testosterone converting to estradiol; SERMs (tamoxifen, raloxifene, clomiphene, enclomiphene) block or activate the receptor depending on the tissue.
- The predicted harm is the same either way and it is not the one people expect. Estrogen is not a side effect to be eliminated — it is required for bone density, joint comfort, lipid handling, libido and mood in men as well as women. Crushing it produces aching joints, flat libido, low mood and, over years, measurable bone loss.
- Clomiphene specifically is a mixture of two isomers and the longer-lived one (zuclomiphene) accumulates; the visual disturbances reported on it are attributed to that accumulation. Enclomiphene is the isolated isomer, which is the entire argument for it.
What has actually been reported
- Well documented in oncology use: hot flushes, joint pain and reduced bone mineral density on AIs; venous thromboembolism and endometrial changes on tamoxifen.
- Visual disturbance on clomiphene is uncommon but real and is a reason to stop rather than push through.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- The dose almost everyone gets wrong is the AI dose. These are used in oncology to drive estradiol as close to zero as possible; that is a cancer-treatment goal and it is the wrong target for anyone else. Most people feeling terrible on a protocol are over-suppressing estradiol.
- Measure before adjusting, and measure with the sensitive (LC-MS/MS) estradiol assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
- If an AI is genuinely needed, the lowest effective dose intermittently beats a fixed daily one. Bone density is worth tracking on anything run for more than a year.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- Sensitive estradiol, total and free testosterone, LH and FSH, a lipid panel, and — for long-term use — a DEXA for bone density.
Don't run this if
- You are only using one because of a number rather than a symptom. An estradiol reading with no symptoms attached is not a reason to medicate.
The honest unknown
- Long-term outcomes of AI use in otherwise healthy men, at the doses used outside oncology, have not been studied. The bone and lipid consequences are extrapolated from populations taking them for a different reason.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get Enclomiphene
Buy Enclomiphene at AlgoRx →Enclomiphene — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Enclomiphene moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Haematocrit and haemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatisation converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Enclomiphene — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
Get the complete breakdown for Enclomiphene — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside Enclomiphene
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| LH & FSH | Enclomiphene works by raising these |
| Total Testosterone | The outcome |
| Estradiol, Sensitive (LC/MS-MS) | Blocking oestrogen receptors changes this reading's meaning |
| SHBG (Sex Hormone-Binding Globulin) | Rises on SERMs, which blunts the free testosterone gain |
The Post-Cycle / Recovery & Fertility panel covers these in one order — 9 markers, $184.50 with the discount applied.
Check results you already have → · All 102 markers A–Z
Enclomiphene — frequently asked questions
What is Enclomiphene?
Enclomiphene (Enclomiphene citrate) is a hormonal & sexual research compound. Estrogen-receptor antagonist at the hypothalamus — removes estrogen's brake so LH/FSH rise and testicular testosterone increases.
Is the full Enclomiphene protocol on this page?
The reported research dose is on this page, along with how Enclomiphene works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of Enclomiphene?
Enclomiphene has an approximate half-life of ~10 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Enclomiphene?
Current evidence level: Human trials. Enclomiphene is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact Enclomiphene protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What Enclomiphene is used for
Enclomiphene appears under 3 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.